Results 31 to 40 of about 144,226 (276)

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study [PDF]

, 2021
PURPOSE: The double-blind, randomized, placebo-controlled phase III iNNOVATE study showed sustained efficacy of ibrutinib-rituximab in Waldenström's macroglobulinemia (WM). Here, we present the final analysis from iNNOVATE.
Matous, Jeffrey V., Trotman, Judith, Varettoni, Marzia, Herbaux, Charles, Heffner, Leonard T., Tam, Constantine S., Hauns, Bernhard, Treon, Steven P., Buske, Christian, Tedeschi, Alessandra, García-Sanz, Ramón, MacDonald, David, Palomba, M. Lia, Arango-Hisijara, Israel, Mahe, Beatrice, Leblond, Veronique, Dimopoulos, Meletios A., Shustik, Chaim, Kastritis, Efstathios, Ping, Jerry   +19 more
core   +1 more source

Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey

Pharmaceuticals, 2014
Biologics such as rituximab are an important component of oncology treatment strategies, although access to such therapies is challenging in countries with limited resources.
William H. Baer II, Archana Maini, Ira Jacobs   +2 more
doaj   +1 more source

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

, 2010
Rituximab, a monoclonal antibody which targets CD20 on B-cells, is now central to the treatment of a variety of malignant and autoimmune disorders. Despite this success a substantial proportion of B-cell lymphomas are unresponsive or develop resistance ...
French, R.R., Johnson, P.W.M., Cox, Kerry L., Chan, Claude H.T., Johnston, David A., Glennie, Martin J., Jarrett, T.C., Glennie, M.J., Verbeek, Sjef, Chan, H.T.C., Dixon, S.V., Mora Vidal, Regina, Wijayaweera, Sahan S., Cragg, Mark S., Lim, Sean H., Dixon, Sandra V., Verbeek, J.S., French, Ruth R., Wijayaweera, S.S., Jarrett, Timothy C., Cragg, M.S., Kim, Hyung J., Kerr, Jonathan P., Vidal, R.M., Johnston, D.A., Lim, S.H., Cox, K.L., Kerr, J.P., Johnson, Peter W.M., Beers, Stephen A., Kim, H., Beers, S.A.   +31 more
core   +1 more source

[18F]Fluorodeprenyl‐D2 PET as a Tool to Monitor Disease Activity in GAD65‐Ab Autoimmune Encephalitis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate [18F]fluorodeprenyl‐D2 ([18F]F‐DED) positron‐emission tomography (PET) imaging as a biomarker of disease activity in autoimmune encephalitis (AIE) associated with glutamic acid decarboxylase 65 (GAD65) antibodies. Methods [18F]F‐DED PET was performed in 25 GAD65‐AIE patients and 8 controls using dynamic (0–60 min) and ...
Julia S. Dorneich, Jonathan A. Gernert, Hanna Zimmermann, Lisa Tagnin, Marianthi Zeinaki, Laura Sanzo, Letizia Vogler, Elisabeth Kaufmann, Justina Dargvainiene, Frank Leypoldt, Gérard N. Bischof, Robert Perneczky, Boris‐Stephan Rauchmann, Simon Lindner, Günter U. Höglinger, Rudolf A. Werner, Martin Kerschensteiner, Tania Kümpfel, Matthias Brendel, Franziska S. Thaler   +19 more
wiley   +1 more source

Hospitalised infections and rituximab administration among children and adolescents with systemic lupus erythematosus from 2009 to 2021

Lupus Science and Medicine
Background Rituximab is associated with high infection rates, but studies of infections following rituximab in youth with childhood-onset SLE (cSLE) are limited.
Esi M Morgan, Jonathan D Cogen, Jordan E Roberts, Anna V Faino, Mersine A Bryan   +4 more
doaj   +1 more source

Hypokalemia after rituximab administration in nephrotic syndrome: two case reports

BMC Nephrology, 2023
Rituximab, a chimeric anti-CD20 monoclonal antibody, is an effective treatment for nephrotic syndrome. Hypokalemia is a rare adverse reaction among patients treated with rituximab although there have been extensive reports of acute and chronic adverse ...
Yiyun Song, Lin Ding, Xin An, Yi Zhao, Xianhua Li, Xiangdong Yang, Xiaoyan Xiao   +6 more
doaj   +1 more source

HIV-associated multi-centric Castleman’s disease with multiple organ failure: cuccessful treatment with rituximab [PDF]

, 2010
Introduction: Multicentric Castleman's Disease (MCD), a lymphoproliferative disorder associated with Human Herpes Virus-8 (HHV-8) infection, is increasing in incidence amongst HIV patients.
Johns, RH, Lipman, M, Agarwal, B, Cwynarski, K, Doyle, T, Isaacson, PG, Cleverley, JR, Shaw, S   +7 more
core  

Primary vs. Secondary Antibody Deficiency: Clinical Features and Infection Outcomes of Immunoglobulin Replacement [PDF]

, 2014
Secondary antibody deficiency can occur as a result of haematological malignancies or certain medications, but not much is known about the clinical and immunological features of this group of patients as a whole. Here we describe a cohort of 167 patients
Matthew Buckland (589995), Lorena Lorenzo (589997), Matthew Buckland, Dempster, J, Duraisingham Sai S., Longhurst Hilary J., Matthew Buckl, Sai S. Duraisingham, Sofia Grigoriadou (589998), Sai S Duraisingham, Hilary J Longhurst, John Dempster, Dempster John, Grigoriadou Sofia, Duraisingham, SS, Lorenzo, L, Buckland Matthew, Grigoriadou, S, Sofia Grigoriadou, Lorenzo Lorena, Sai S. Duraisingham (589994), Buckland, M, Longhurst, HJ, Lorena Lorenzo, John Dempster (589996), Buckland, MS, Hilary J. Longhurst (589999), Hilary J. Longhurst   +27 more
core   +2 more sources

Understanding Further the Phenotypic Spectrum of Central Nervous System Inflammatory Demyelinating Disorders Using Unsupervised Clustering

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap.
Bade Gulec, Elif Everest, Melih Tutuncu, Ugur Bilge, Sabahattin Saip, Ugur Uygunoglu, Aksel Siva   +6 more
wiley   +1 more source

Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases

Turkish Journal of Hematology, 2017
Objective: This paper prospectively evaluates the long-term followup [mean +- standard deviation (SD) duration: 89.7+-19.4 months] data of 15 patients (13 females and 2 males) with refractory symptomatic immune thrombocytopenia (ITP) treated with ...
Fehmi Hindilerden, Ipek Yönal Hindilerden, Mustafa Nuri Yenerel, Meliha Nalçacı, Reyhan Diz Küçükkaya   +4 more
doaj   +1 more source